The recent headlines and the huge Trump following have helped closed the gap on Clinton, and if Trump is declared the winner, we could see a large market drop next week.
The relentless populist rhetoric has lowered the prices on some of the top pharmaceutical companies, and long-term growth and income investors have a chance to buy some great stocks on sale.
A UBS research report notes the segments of the economy that may disproportionately benefit as all the money that baby boomers had stashed away in savings, pensions, IRAs and 401(k) plans starts…
Eli Lilly plans to release its most recent earnings report before the markets open on Tuesday, and analysts expect top and bottom line growth.
Chris Lange Alkermes' positive Phase 3 results for its novel antidepressant is serving as a rising tide — a storm surge even — for many biotech companies in the depression space.
A recent Merrill Lynch research features a big move by adding a top consumer goods company to the firm's well-respected US 1 list.
A new Jefferies research report features top pharmaceutical picks for the fourth quarter. Any of these top picks make good sense for long-term growth and income portfolios.
One smart thing for growth stock buyers is to focus on total return and buy large cap quality stocks that will do well regardless of the near-term economic news.
Eli Lilly shares had a bit of a boost on Wednesday after it was announced that one of its subsidiaries would be acquiring Boehringer Ingelheim Vetmedica.
Chris Lange A recent Merrill Lynch research report features the firm's top ideas for the fourth quarter. These eight stocks look like outstanding picks for growth stock accounts.
Any of these three top pharmaceutical companies makes an outstanding addition to more conservative portfolios. They are also far less volatile and act better than biotechs if the market gets dicey.
If there is one trend that has worked in America, it is the trend of betting on the public taking care of their pets. Now Merrill Lynch has issued a report on…
In a recent research note, the analysts at Merrill Lynch make a big move by adding a top utility company to the firm's well-respected US 1 list of stocks to Buy.
Despite recent market headwinds and volatility, there are strong underlying fundamentals among the large cap pharmaceuticals that are continuing to drive them forward.
Investors never take kindly to a 2.45% sell-off, like the one seen in the S&P 500, and they may be looking to shift into dividend-paying large caps, which will remain in demand…
